Navigation Links
Care-Tech Laboratories Agrees to Stop Making, Selling and Distributing Unapproved Antimicrobial Products
Date:9/8/2009

WASHINGTON, Sept. 8 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today announced that St. Louis-based Care-Tech Laboratories Inc. and its principal officers, John C. Brereton and Sherry L. Brereton, have signed a consent decree, agreeing to stop the illegal manufacture, marketing, and distribution of over-the-counter (OTC) antimicrobial drugs used to treat and prevent infection.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)

Inspectors found that Care-Tech violated numerous provisions of the FDA's current good manufacturing practice (cGMP) regulations that direct how antimicrobial drugs are made. Additionally, the products do not conform to any applicable regulations for OTC drug products and have not undergone an FDA review, and therefore are considered unapproved drug products.

Under the terms of the consent decree, Care-Tech may not resume manufacturing and distribution of the drugs until it corrects these and other violations.

"The FDA is concerned about Care-Tech's products because they lack FDA approval, do not conform to any applicable over-the-counter drug monograph, and are not appropriately manufactured," said Deborah Autor, director of the FDA's Office of Compliance, Center for Drug Evaluation and Research. "Companies have an obligation to consumers to ensure that their products are safe, effective, and high quality, and the FDA recommends that Care-Tech's customers seek alternative products."

Care-Tech products are sold online and through telephone orders to hospitals, nursing homes and other health care facilities. They are not sold in retail stores. The FDA is not aware of any reports of injury or illness related to the use of these products. Consumers should contact Care-Tech at 1-800-325-9681 to return products in their possession, which include:

Barri-Care

Care-Creme

Caricia Care

CC-500

Clinical Care

Consept

Formula Magic

Humatrix

Loving Lather

Loving Lather II

Loving Lotion

Orchid Fresh II

Satin

Tech 2000

Techni-Care

Urban Skin

Health care professionals and consumers may report serious adverse events (side effects) or quality problems for these or any products to the FDA's MedWatch Adverse Event Reporting program, online, or by regular mail, fax or phone.

For more information:

Facts About Current Good Manufacturing Practices (cGMPs)

Media Inquiries: Christopher Kelly, 301-796-4676, christopher.kelly@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. Announces Reversal of Summary Judgment in Ultracet(R) ANDA Patent Litigation
2. Breckenridge Pharmaceutical Enters Agreement with Orit Laboratories (West Caldwell, NJ) to Market Ergocalciferol (Vitamin D) Capsules
3. AUDIO from Medialink and Forest Laboratories: Dangers of Switching Medications
4. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Imitrex(R) Tablets
5. Nycomed and Forest Laboratories to Collaborate on US Commercialisation of Daxas(R) in COPD
6. Caraco Pharmaceutical Laboratories, Ltd. Announces Settlement of Ethyol(R) ANDA Patent Litigation
7. Roxane Laboratories, Inc. Announces the Launch of Risperidone Oral Solution 1mg/mL
8. Caraco Pharmaceutical Laboratories, Ltd. Announces Change to Executive Team as Jitendra N. Doshi Assumes Position of CEO
9. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2010
10. Leading health organizations launch new accreditation process for laboratories across Africa
11. IDEXX Laboratories Announces Second Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... January 24, 2017 , ... Attention women who want bigger ... that autologous fat grafting—taking one’s own fat and putting it in other body ... , Cosmetic Surgeon and Medical Director of MilfordMD Cosmetic Dermatology Surgery & Laser ...
(Date:1/24/2017)... (PRWEB) , ... January 23, 2017 , ... ... the following statement on the imposition of the Mexico City Policy, also known ... policy, enacted again today through Executive action, prohibits foreign non-governmental organizations from receiving ...
(Date:1/24/2017)... ... January 23, 2017 , ... ... support them, Dr. Carol Francis, Psychologist in the South Bay area , ... respectful governing for all people and by all people shines as a bright ...
(Date:1/23/2017)... ... January 23, 2017 , ... PKF O’Connor Davies , LLP, the nation’s ... accountant at the Firm, will participate in the 40th Annual "Empire State Building Run ... race up 1,576 steps, a vertical distance equal to about a fifth of a ...
(Date:1/23/2017)... ... January 23, 2017 , ... The ... standards for healthcare treatment providers who treat the full spectrum of eating disorder ... , The Presidents Council consists of the leading eating disorder treatments centers located ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... The global  active pharmaceutical ingredients (API) market  is ... on a new report by Grand View Research, Inc. The rising prevalence ... market over the forecast period. Advancements in recombinant molecular technologies and high ... Continue Reading ... ...
(Date:1/24/2017)... , January 24, 2017 Aptuit, ... Molecular Surgical Laboratory des Massachusetts General Hospital (MGH) unter ... geht es um die Identifizierung und Validierung neuartiger Targets ... dass sie der Resistenz von Antibiotika bei der Behandlung ... ...
(Date:1/24/2017)... , Jan. 23, 2017 Laboratory Markets ... global use of mass spectrometry in both clinical and ... ,MS analysis, global market size of $6.8 billion and ... next four years, profiles the use of mass spectrometry ... 21 countries. This study investigated growth in the use ...
Breaking Medicine Technology: